Yohann Dabi1, Yohann Rouscoff1, Julien Anract1, Nicolas Barry Delongchamps1, Mathilde Sibony2, Djillali Saighi1, Marc Zerbib1, Michael Peyraumore1, Evanguelos Xylinas3. 1. Department of Urology, Cochin Hospital, APHP, Paris Descartes University, 27, rue du Faubourg Saint-Jacques, 75014, Paris, France. 2. Department of Pathology, Cochin Hospital, APHP, Paris Descartes University, 27, rue du Faubourg Saint-Jacques, 75014, Paris, France. 3. Department of Urology, Cochin Hospital, APHP, Paris Descartes University, 27, rue du Faubourg Saint-Jacques, 75014, Paris, France. evanguelosxylinas@hotmail.com.
Abstract
PURPOSE: Body mass index (BMI) has been associated with worse outcomes in several solid malignancies. We aimed to evaluate the association between BMI and oncological outcomes in patients treated with radical cystectomy (RC) for muscle-invasive urothelial carcinoma of the bladder (UCB). METHODS: We retrospectively reviewed 701 consecutive patients treated with RC and pelvic lymphadenectomy for UCB at our institution between 1995 and 2011. Univariable and multivariable Cox regression models investigated the association of BMI with disease recurrence and cancer-specific mortality. BMI was analyzed as both continuous and categorical variable (<25 vs. 25-29 vs. ≥30 kg/m2). RESULTS: From the 701 patients, 275 (39.2 %) had a BMI < 25 kg/m2, 280 (39.9 %) had a BMI between 25 and 29.9 kg/m2, and 146 (20.9 %) had a BMI ⩾ 30 kg/m2. Within a median follow-up of 45 months (IQR 23-75), 163 patients (23.3 %) experienced a disease recurrence and 127 (18.1 %) died from the disease. In univariable analyses, BMI ⩾ 30 kg/m2 was associated with a higher risk of disease recurrence and cancer-specific mortality (both p values <0.01). In multivariable analyses that adjusted for the effects of standard clinicopathological features, BMI ⩾ 30 kg/m2 was associated with both higher risks of disease recurrence (HR 1.58; 95 % CI 1.06-2.34, p = 0.02) and cancer-specific mortality (HR 1.58; 95 % CI 1.01-2.48; p = 0.04). CONCLUSIONS: Obesity was independently associated with higher risks of disease recurrence and cancer-specific mortality in patients treated with RC for muscle-invasive UCB. BMI is a modifiable feature that may have significant individual and public health implications in patients with muscle-invasive UCB.
PURPOSE: Body mass index (BMI) has been associated with worse outcomes in several solid malignancies. We aimed to evaluate the association between BMI and oncological outcomes in patients treated with radical cystectomy (RC) for muscle-invasive urothelial carcinoma of the bladder (UCB). METHODS: We retrospectively reviewed 701 consecutive patients treated with RC and pelvic lymphadenectomy for UCB at our institution between 1995 and 2011. Univariable and multivariable Cox regression models investigated the association of BMI with disease recurrence and cancer-specific mortality. BMI was analyzed as both continuous and categorical variable (<25 vs. 25-29 vs. ≥30 kg/m2). RESULTS: From the 701 patients, 275 (39.2 %) had a BMI < 25 kg/m2, 280 (39.9 %) had a BMI between 25 and 29.9 kg/m2, and 146 (20.9 %) had a BMI ⩾ 30 kg/m2. Within a median follow-up of 45 months (IQR 23-75), 163 patients (23.3 %) experienced a disease recurrence and 127 (18.1 %) died from the disease. In univariable analyses, BMI ⩾ 30 kg/m2 was associated with a higher risk of disease recurrence and cancer-specific mortality (both p values <0.01). In multivariable analyses that adjusted for the effects of standard clinicopathological features, BMI ⩾ 30 kg/m2 was associated with both higher risks of disease recurrence (HR 1.58; 95 % CI 1.06-2.34, p = 0.02) and cancer-specific mortality (HR 1.58; 95 % CI 1.01-2.48; p = 0.04). CONCLUSIONS: Obesity was independently associated with higher risks of disease recurrence and cancer-specific mortality in patients treated with RC for muscle-invasive UCB. BMI is a modifiable feature that may have significant individual and public health implications in patients with muscle-invasive UCB.
Authors: Michael Rink; Evanguelos Xylinas; Marko Babjuk; Jens Hansen; Armin Pycha; Evi Comploj; Yair Lotan; Maxine Sun; Pierre I Karakiewicz; Joual Abdennabi; Harun Fajkovic; Wolfgang Loidl; Felix K Chun; Margit Fisch; Douglas S Scherr; Shahrokh F Shariat Journal: J Urol Date: 2012-10-18 Impact factor: 7.450
Authors: A M Suikkari; V A Koivisto; E M Rutanen; H Yki-Järvinen; S L Karonen; M Seppälä Journal: J Clin Endocrinol Metab Date: 1988-02 Impact factor: 5.958
Authors: Sarah P Psutka; Alonso Carrasco; Grant D Schmit; Michael R Moynagh; Stephen A Boorjian; Igor Frank; Suzanne B Stewart; Prabin Thapa; Robert F Tarrell; John C Cheville; Matthew K Tollefson Journal: Cancer Date: 2014-05-19 Impact factor: 6.860
Authors: Behfar Ehdaie; Thomas F Chromecki; Richard K Lee; Yair Lotan; Vitaly Margulis; Pierre I Karakiewicz; Giacomo Novara; Jay D Raman; Casey Ng; William T Lowrance; Douglas S Scherr; Shahrokh F Shariat Journal: J Urol Date: 2011-05-14 Impact factor: 7.450
Authors: Michael Rink; Emily C Zabor; Helena Furberg; Evanguelos Xylinas; Behfar Ehdaie; Giacomo Novara; Marko Babjuk; Armin Pycha; Yair Lotan; Quoc-Dien Trinh; Felix K Chun; Richard K Lee; Pierre I Karakiewicz; Margit Fisch; Brian D Robinson; Douglas S Scherr; Shahrokh F Shariat Journal: Eur Urol Date: 2012-11-27 Impact factor: 20.096
Authors: Cheryl T Lee; Rodney L Dunn; Bert T Chen; Daya P Joshi; Jaqueline Sheffield; James E Montie Journal: J Urol Date: 2004-10 Impact factor: 7.450
Authors: Tobias Maurer; Jean Maurer; Margitta Retz; Roger Paul; Niko Zantl; Jurgen E Gschwend; Uwe Treiber Journal: Urol Int Date: 2009-06-08 Impact factor: 2.089
Authors: Ellen Westhoff; J Alfred Witjes; Neil E Fleshner; Seth P Lerner; Shahrokh F Shariat; Gunnar Steineck; Ellen Kampman; Lambertus A Kiemeney; Alina Vrieling Journal: Bladder Cancer Date: 2018-01-20
Authors: Andrea Mari; Riccardo Campi; Riccardo Tellini; Giorgio Gandaglia; Simone Albisinni; Mohammad Abufaraj; Georgios Hatzichristodoulou; Francesco Montorsi; Roland van Velthoven; Marco Carini; Andrea Minervini; Shahrokh F Shariat Journal: World J Urol Date: 2017-11-16 Impact factor: 4.226